IPCALAB

Signed tech transfer & JD

signed a technology transfer and joint development agreement with BioSimilar Sciences PR LLC for a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. The agreement will transfer development and manufacturing to BSS' Puerto Rico campus, with BSS receiving exclusive US/Canada rights. First biosimilar launch planned for 2027.